Content about European Union

May 7, 2013
U.S. to contribute to 'rapid' biosimilar market growth through 2023, study finds

The global market for biosimilars will be worth nearly $2.5 billion this year, according to a new study.

LONDON — The global market for biosimilars will be worth nearly $2.5 billion this year, according to a new study.

The study, by British market research firm Visiongain, forecast that the $2.445 billion market size marked more than 20% of growth from 2012 and would account for about 2% of the overall market for biologics. The market is expected to grow rapidly through 2023 as biosimilars hit the market in the United States and European Union.

May 2, 2013
Beiersdorf off to 'good start' for 2013

Skin care brand Beiersdorf announced on Thursday that it has “continued last year’s positive trend in the first quarter of 2013.”

HAMBURG, Germany — Skin care brand Beiersdorf announced on Thursday that it has “continued last year’s positive trend in the first quarter of 2013.”

Organic group sales rose by 5.4%, and nominal sales increased by 2.9%, from €1,533 million to €1,577 million. The key driver for this positive performance was the double-digit sales growth recorded in emerging markets, the company stated. Consolidated profit after tax rose to €155 million.
 

January 30, 2013
Campaigners celebrate as EU set to ban animal testing for cosmetics

A ban on importing and selling animal-tested cosmetics products and ingredients will enter into force in March. The ban affects all cosmetics, including toiletries and beauty products.

LONDON — A ban on importing and selling animal-tested cosmetics products and ingredients will enter into force in March. The ban affects all cosmetics, including toiletries and beauty products.

"I believe that the ban should enter into force in March 2013 as Parliament and Council already have decided. I therefore am not planning to propose a postponement or derogation to the ban," Commissioner Tonio Borg wrote in a recent letter to animal testing campaigners.

November 12, 2012
Reports: P&G, Teva partner on European OTC company called PGT Healthcare, gain EU approval

Procter & Gamble and Teva Pharmaceutical on Monday gained European Union approval for a joint venture on the sale of nonprescription medicines to be called PGT Healthcare, according to published reports.

CINCINNATI — Procter & Gamble and Teva Pharmaceutical on Monday gained European Union approval for a joint venture on the sale of nonprescription medicines to be called PGT Healthcare, according to published reports. 

According to the reports, the joint venture didn't raise competition concerns. P&G will have a 51% stake in the venture. 

 

 

December 23, 2011
12 for 2012

Rather than take off for Christmas, the editors of Drug Store News took a look at the year ahead and the stories, issues and trends that will make headlines in retail pharmacy in 2012.

Rather than take off for Christmas, the editors of Drug Store News took a look at the year ahead and the stories, issues and trends that will make headlines in retail pharmacy in 2012.

August 24, 2011
Counterfeit threat intensifies


A worldwide flood of counterfeit and unsafe medications is seeping into the United States and other developed countries via the Internet and porous borders, threatening public health and the security of the pharmaceutical supply chain.


A worldwide flood of counterfeit and unsafe medications is seeping into the United States and other developed countries via the Internet and porous borders, threatening public health and the security of the pharmaceutical supply chain. In response, federal drug safety overseers and such drug manufacturers as Pfizer are working to shore up the integrity of drug supplies and stop production of fake and adulterated pharmaceuticals at their source.


June 6, 2011
FDA issues statement on E. coli outbreak in Europe

The Food and Drug Administration on Friday addressed the current outbreak of E. coli O104 in Europe.

SILVER SPRING, Md. — The Food and Drug Administration on Friday addressed the current outbreak of E. coli O104 in Europe.

The U.S. regulatory agency said that it has been in "routine contact" with the Centers of Disease Control and Prevention and the European Union to monitor the current outbreak of E. coli O104 and to track any illnesses in the United States that may be related to the outbreak.

May 17, 2011
Study: Pirfenidone may improve lung function among IPF patients

An investigational drug made by InterMune improved breathing in patients with a rare and fatal lung disease, according to results of a late-stage clinical trial published online in The Lancet last week.

BRISBANE, Calif. — An investigational drug made by InterMune improved breathing in patients with a rare and fatal lung disease, according to results of a late-stage clinical trial published online in The Lancet last week.

InterMune is investigating the drug pirfenidone as a treatment for idiopathic pulmonary fibrosis, which affects more than 200,000 patients in the European Union and the United States combined. Only 20% of patients with IPF survive after five years.

March 29, 2011
Datamonitor: Global biosimilars market to reach nearly $4 billion by 2015

Any manufacturer that has the necessary resources and still is hesitating about whether to tap into biosimilars might want to go ahead and do it, if projections by British market analysis firm Datamonitor come true.

LONDON — Any manufacturer that has the necessary resources and still is hesitating about whether to tap into biosimilars might want to go ahead and do it, if projections by British market analysis firm Datamonitor come true.

The firm released a report Monday showing that the global biosimilars market, whose value stood at $243 million in 2010, will increase to $3.7 billion by 2015.

July 11, 2010
Ranir acquires Synpart biz from HemCon Medical Technologies

Ranir, an oral care consumer products company, has acquired Synpart Limited and Synpart AG from...